Academic Journal
Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
| العنوان: | Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies |
|---|---|
| المؤلفون: | Schulz, Felicitas, Jäger, Paul, Tischer, Johanna, Fraccaroli, Alessia, Bug, Gesine, Hausmann, Andreas, Baermann, Ben-Niklas, Tressin, Patrick, Hoelscher, Alexander, Kasprzak, Annika, Nachtkamp, Kathrin, Schetelig, Johannes, Hilgendorf, Inken, Germing, Ulrich, Dietrich, Sascha, Kobbe, Guido |
| المساهمون: | Ying, Mingyao |
| سنة النشر: | 2024 |
| المجموعة: | Digital Library Thüringen |
| مصطلحات موضوعية: | article, ScholarlyArticle, ddc:610, FLAMSA, allogeneic transplant (aHSCT), sequential conditioning, AML, MDS, myeloid malignancies, reduced-intensity conditioning, RIC, venetoclax |
| الوصف: | Up to 50% of patients with high-risk myeloid malignancies die of relapse after allogeneic stem cell transplantation. Current sequential conditioning regimens like the FLAMSA protocol combine intensive induction therapy with TBI or alkylators. Venetoclax has synergistic effects to chemotherapy. In a retrospective survey among German transplant centers, we identified 61 patients with myeloid malignancies that had received FLAMSA-based sequential conditioning with venetoclax between 2018 and 2022 as an individualized treatment approach. Sixty patients (98%) had active disease at transplant and 74% had genetic high-risk features. Patients received allografts from matched unrelated, matched related, or mismatched donors. Tumor lysis syndrome occurred in two patients but no significant non-hematologic toxicity related to venetoclax was observed. On day +30, 55 patients (90%) were in complete remission. Acute GvHD II°–IV° occurred in 17 (28%) and moderate/severe chronic GvHD in 7 patients (12%). Event-free survival and overall survival were 64% and 80% at 1 year as well as 57% and 75% at 2 years, respectively. The off-label combination of sequential FLAMSA-RIC with venetoclax appears to be safe and highly effective. To further validate these insights and enhance the idea of smart conditioning, a controlled prospective clinical trial was initiated in July 2023. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | 12 Seiten |
| اللغة: | English |
| Relation: | Cancers -- Cancers (Basel) -- 2072-6694 -- 2527080-1 -- http://uri.gbv.de/document/gvk:ppn:614095670; https://doi.org/10.3390/cancers16030532 |
| DOI: | 10.3390/cancers16030532 |
| الاتاحة: | https://doi.org/10.3390/cancers16030532 https://nbn-resolving.org/urn:nbn:de:gbv:27-dbt-60376-3 https://www.db-thueringen.de/receive/dbt_mods_00060376 https://www.db-thueringen.de/servlets/MCRFileNodeServlet/dbt_derivate_00062969/cancers-16-00532.pdf |
| Rights: | https://creativecommons.org/licenses/by/4.0/ ; public ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.9F26EC2C |
| قاعدة البيانات: | BASE |
| DOI: | 10.3390/cancers16030532 |
|---|